[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360019-105":59,"doc-detail-360019-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ihc-p53-performance-in-nordiqc-recalibration-of-ihc-assays-is-needed","IHC p53 Performance in NordiQC - Recalibration of IHC Assays is Needed","","TP53 is the most frequently mutated gene in human cancers, with alterations in 50% of malignancies. Optimized p53 immunohistochemistry (IHC) can reliably act as a surrogate for detecting TP53 mutations, but many laboratories struggle to recognize p53 IHC patterns beyond overexpression, especially absence, cytoplasmic, and wild-type patterns. Using data from six consecutive NordiQC external quality assessment rounds (2007–2024), this study evaluates 1,796 submitted p53 IHC assays.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ihc-p53-performance-in-nordiqc-recalibration-of-ihc-assays-is-needed/360019/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ihc-p53-performance-in-nordiqc-recalibration-of-ihc-assays-is-needed/360019.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is p53 immunohistochemistry (IHC) important for TP53 mutation detection?","Question",{"text":112,"@type":113},"When properly optimized, p53 IHC can serve as a reliable surrogate for detecting TP53 mutations, offering a faster and more cost-effective alternative to molecular testing.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What additional p53 IHC patterns were recognized after NordiQC updated its assessment in 2021?",{"text":117,"@type":113},"The assessment was updated to include wild-type and absence patterns, increasing the complexity of interpreting p53 IHC reactions beyond overexpression.",{"name":119,"@type":110,"acceptedAnswer":120},"What problem did the study identify with ready-to-use p53 IHC products?",{"text":121,"@type":113},"Ready-to-use products performed suboptimally because they are calibrated mainly to detect overexpression, which can produce false-negative or overly weak results for other mutation-associated patterns.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360019,1790197095,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","RESEARCH ARTICLE  \nIHC p53 Performance in NordiQC: Recalibration of IHC Assays is Needed  \nKristi Bøgh Anderson, MD, *† Søren Nielsen, BMS, * and Rasmus Røge, MD, PhD *†  \nAbstract: The TP53 gene is the most frequently∼mutated gene in  \nhuman cancers, with alterations occurring in 50% of all malignancies. When properly optimized, p53 immunohistochemistry (IHC) can serve as a reliable surrogate for detecting TP53 mutations. However, many laboratories struggle to identify p53 IHC reaction patterns beyond overexpression, particularly the absence, cytoplasmic, and wild-type patterns. Asthe clinical relevance of these additional patterns became recognized, NordiQC updated its assessment in 2021 to include wild-type and absence patterns, thereby increasing the complexity of p53 IHC and revealing widespread difficulties across laboratories. In this study, we analyze data from 6 consecutive NordiQC external quality assessment rounds from 2007 to 2024, covering 1,796 submitted p53 IHC assays. Our findings show that while most laboratories can reliably detect high antigen expression of overexpression, many protocols fail to adequately demonstrate low-level p53 expression, limiting the validity of the IHC assay. Ready-To-Use products, particularly when used according to manufacturer recommendations, performed suboptimally. These kits are calibrated exclusively to detect overexpression, leading to false-negative or too-weak results for other mutation-associated patterns. Our data represents the most comprehensive evaluation of p53 IHC assay performance to date. The findings underscore an urgent need to recalibrate p53 IHC protocols, with a special focus on improving analytical sensitivity and ensuring consistent use of both internal and external controls. Aligning IHC assays calibrated to identify the full spectrum of TP53 mutations, including those that result in absent and wild-type patterns, can significantly enhance the diagnostic accuracy of p53 IHC.  \nKey Words: TP53, p53 immunohistochemistry, mutation-associated  \nReceived for publication December 12, 2025; accepted February 16, 2026.  \nFrom the *Department of Pathology, Aalborg University Hospital, NordiQC; and †Department of Clinical Medicine, The Faculty of Medicine, Aalborg University, Gistrup, Denmark.  \nThe authors declare no conflict of interest.  \nReprints: Kristi Bøgh Anderson, MD, Department of Pathology, Aalborg Universitetshospital, in English would be Aalborg University Hospital Gistrup, Denmark (e-mail: [kristi.anderson@rn.dk](kristi.anderson@rn.dk)) .  \nCopyright © 2026 The Author(s) . Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.  \nDOI: 10. 1097/PAI.0000000000001314  \nstaining patterns, analytical sensitivity, immunohistochemistry optimization, external quality assessment, NordiQC, diagnostic accuracy, assay calibration, laboratory performance  \n(Appl Immunohistochem Mol Morphol 2026;34:166–171)  \nThe p53 protein, encoded by the TP53 gene, plays a  \ncentral role in regulating cell growth and division. When DNA damage is detected, p53 either pauses the cell cycle to allow for repair or induces apoptosis when repair is not possible, preventing potential tumor formation.1 The TP53 gene is the most frequent mutated gene in  \ncancers, with mutations occurring in 50% of cases.1–5  \nIn normal, nonmutated cells, p53 levels are tightly regulated by rapid MDM2-mediated degradation, resulting in low protein levels with limited immunohistochemical detectability. The characteristic p53 reaction pattern seen in normal cells is a wild-type pattern, showing varying nuclear reaction intensities across cells, ranging from negative to strongly positive and hetero","cbCaie2vJlf48ztF","https://ap.wps.com/l/cbCaie2vJlf48ztF","pdf",23579208,"English","# Abstract\n## Background and clinical need\n## Study design and dataset\n## Key findings and limitations\n## Implications for recalibration","[{\"question\":\"Why is p53 immunohistochemistry (IHC) important for TP53 mutation detection?\",\"answer\":\"When properly optimized, p53 IHC can serve as a reliable surrogate for detecting TP53 mutations, offering a faster and more cost-effective alternative to molecular testing.\"},{\"question\":\"What additional p53 IHC patterns were recognized after NordiQC updated its assessment in 2021?\",\"answer\":\"The assessment was updated to include wild-type and absence patterns, increasing the complexity of interpreting p53 IHC reactions beyond overexpression.\"},{\"question\":\"What problem did the study identify with ready-to-use p53 IHC products?\",\"answer\":\"Ready-to-use products performed suboptimally because they are calibrated mainly to detect overexpression, which can produce false-negative or overly weak results for other mutation-associated patterns.\"}]","IHC p53 Performance in NordiQC - Recalibration of IHC Assays is Needed | PDF",1790138519,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b696b0d7acd45e95db8cd33a06bec49.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4d03c822228ae995edbc2c3b697b525.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9dc55d19d14636659bbf726ab690f58b.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8c5fd80df9ed1058d3889b01d7bc2b1.webp",980,1311]